Insmed Incorporated (INSM) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Insmed Incorporated
Address
700 US Highway 202/206
Bridgewater, NJ 08807
United States of America (the)
Phone
908 977 9900
Website
Sector
Healthcare
Industry
Biotechnology
Employees
1664
First IPO Date
June 01, 2000
Key Executives
| Name | Title | Pay | Year Born |
| William H. Lewis | President, Chief Executive Officer & Chairman | 2.47M | 1969 |
| S. Nicole Schaeffer | Chief People Strategy Officer | 660,810 | 1968 |
| Sara Bonstein | Chief Financial Officer | 1.12M | 1981 |
| Michael Alexander Smith | Chief Legal Officer & Corporate Secretary | 1.14M | 1978 |
| Roger Adsett | Chief Operating Officer | 1.19M | 1969 |
| Martina Flammer | Chief Medical Officer | 1.22M | 1964 |
| Bryan Dunn | Vice President of Investor Relations | 0 | N/A |
| Brian K. Kaspar | Chief Scientific Officer | 0 | 1974 |
| Christie Camelio | Chief Compliance Officer | 0 | N/A |
| Claire Mulhearn | Vice President of Corporate Communications | 0 | N/A |
Description
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
